

Review

Sarcopenia: A Contemporary Health Problem among Older Adult Populations

Sousana K. Papadopoulou 

Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, 57001 Thessaloniki, Greece; souzapa@gmail.com; Tel.: +30-6944798916

Received: 2 March 2020; Accepted: 26 April 2020; Published: 1 May 2020



Abstract: Sarcopenia, a geriatric disease characterized by a progressive loss of skeletal muscle mass and loss of muscle function, constitutes a rising, often undiagnosed health problem. Its prevalence in the elderly population is largely considered variable, as it ranges from 5% to 50% depending on gender, age, pathological conditions as well as diagnostic criteria. There is no one unified approach of treatment or assessment, which makes sarcopenia even harder to assess. There is a pressing need to provide better diagnosis, diagnostics, prevention, and individualized health care. Physical activity and nutrition are the main studied ways to prevent sarcopenia, and they also offer better outcomes. This review aims to report the prevalence of sarcopenia in older adults, its etiology, prevention, and treatment techniques.

Keywords: sarcopenia; exercise; nutrition; supplements; older adults; muscle mass; frailty

1. Introduction

Sarcopenia is predominantly a geriatric condition, with a gradual loss of skeletal muscle mass and a loss of muscle function [1], first described by Rosenberg [2]. It is one of the leading health issues in the older adults, and it increases disability risk, falls as well as injuries related to falls, hospitalization, limitation of independence, and mortality [3]. Risk factors for sarcopenia include age, gender, level of physical activity, and the presence of chronic disease as well as human immunodeficiency virus (HIV) [4–7]. Its incidence varies widely depending on the population surveyed (such as variations in sex, age, ethnicity, and body composition between various ethnic groups), living conditions (hospitalized, community dwelling, and nursing homes), and assessment tools and methods. In fact, there are several definitions for sarcopenia, with no consensus, hence its prevalence may vary widely [8]. This review aims to report the prevalence of sarcopenia within the older adult age group, its etiology, prevention, and treatment techniques.

2. Pathophysiology

Sarcopenia is a multifactorial disease [9], with a few of its identified contributing factors being low levels of physical activity—likely being a contribution to muscle mass decline—[10,11], decreased caloric intake [12], progressive increase in fibrosis, muscle metabolism changes, chronic inflammatory state, oxidative stress, and neuromuscular junction degeneration [13].

The cellular and molecular mechanisms behind sarcopenia are well described by Riuzzi et al. [14].

Low levels of physical activity are among the main risk factors for sarcopenia, along with the muscle fiber decline [15] that begins in midlife. A gradual loss of muscle fibers begins at 50 years and approximately 50% of the fibers are lost by the age of 80, while the muscle fiber loss is also seen in athletes [15].

In addition to this, hormonal changes with age in growth hormone, testosterone, thyroid hormone, and insulin-like growth factor lead to muscle mass and muscle strength loss, in conjunction with

catabolic signals by tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6) [13], which are in imbalance with the anabolic signals [16]. Furthermore, inadequate nutrient intake and low protein synthesis are common in older adults, while a buildup of lipofuscin and cross-linked proteins in skeletal muscles has been proposed as a factor for low muscle strength in people with sarcopenia [17]. Moreover, another cause of sarcopenia that has been proposed is the failure of satellite cell activation in the muscle [13].

From a histological point of view, it has been found that the sarcopenic state affects the type II muscle fibers with the effect of decreasing their amount, their size, and the number of their mitochondria [18,19]. Among older adults in particular, food consumption has been recorded to be reduced by 25% [20], with quality of food intake, being significantly compromised [21]. Reduced protein intake and low vitamin D levels have also been found to correlate with the diminished muscle strength [10,22,23]. Hormonal decline associated with aging is also likely to impact the loss of muscle mass, with reduced amounts of testosterone and estrogen in men and women, respectively [23–26].

Chronic inflammation is a contributing factor to almost every known disease [27–29]. Aging is characterized by an increase in inflammatory markers and its related factors. Aging-related inflammation in the absence of infection is characterized as low-grade, chronic, and systemic, resulting in responses that contribute to degeneration of tissues. Aging-related inflammation is expected to result from a decreased immune response or lifelong exposure to antigenic stimuli [30,31], resulting in the development of reactive oxygen species and tissue damage via the release of cytokines mediated by the innate and acquired immune system [32]. In action, age-related inflammation is followed by age-related decrease in the number of T and B cells, along with a rise in natural killer cells [33], and tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), interleukin-1 (IL-1), and C-reactive protein (CRP) [34,35]. Subsequently, it is proposed that such cytokines contribute to a predisposition to sarcopenia by triggering the ubiquitin–protease system [36,37]. This altered activation of the cell signaling pathway is known to promote the inflammatory state irrespective of tissue damage or antigenic exposure, further leading to one of the pathogenetic bases that underlie sarcopenia [38,39]. This state also leads to anabolic resistance, which is one of the major determinants of sarcopenia, suggesting that the skeletal muscle protein synthesis in response to physiological stimuli in the older population is below the level of muscle maintenance [40].

Furthermore, myostatin, a protein produced from and released by myocytes affects muscle cell function to inhibit myogenesis [41] by inducing the formation of the SMAD transcription altering protein complex (the main signal transducers for receptors of the transforming growth factor beta (TGF- β) superfamily, which are fundamentally important for adjusting cell development and growth) [42]. The effects of peroxisome proliferator-activated receptor- γ coactivator 1 α (PGC-1 α), a transcriptional coactivator that enhances mitochondrial biogenesis as well as inhibits transcriptional activity of FoxO (a family of proteins crucial in regulating the expression of genes that play a role in cell growth, proliferation, differentiation, as well as longevity), are also suppressed by myostatin [42]. There is a correlation between elevated myostatin and reduced muscle mass in both animal and human studies making it a potential mediator of sarcopenia as well as a therapeutic target [43–45].

Evidence shows that sarcopenia might be affected by a genetic predisposition. Large-scale genome-wide association studies evaluating the impact of genetic variation on gait speed, lean body mass, and grip strength discovered single nucleotide polymorphisms (SNPs) linked to synaptic function and neural maintenance, skeletal muscle fiber structure and function, and muscle metabolism [12].

There is also evidence connecting the molecular circadian rhythms with the maintenance of skeletal muscle. The circadian clock plays a critical role in many skeletal muscle physiological functions, and it is important to better understand the basic bio-physiological processes underlying those complex interactions. The significance of circadian expression for skeletal muscle structure, function, and metabolism becomes obvious when studying the muscle phenotype in models of molecular clock disruption. The loss of the *Bmal1* (brain and muscle Arnt-like protein 1) gene leading to sarcopenia and multiple pathological muscle disorders was observed to support this, including results such as

decreased mitochondrial density and altered mitochondrial respiration, fiber-type changes, disrupted sarcomeric structure, and restricted function [46,47].

Epidemiological work into health and disease developmental origins has shown that early environmental effects on growth and development may have long-term impacts on human health [48]. Low birth weight is associated with decreased muscle mass and strength in adult life, a sign of a weak early climate [49,50]. One study showed that a substantial decrease in muscle fiber score is associated with lower birth weight, suggesting that developmental influences on muscle morphology may explain the association between low birth weight and sarcopenia [51].

3. Diagnosis

There are several diagnostic guidelines concerning sarcopenia. The major ones are the European Working Group on Sarcopenia in Older People (EWGSOP), the International Working Group on Sarcopenia (IWGS), the Asian Working Group for Sarcopenia (AWGS), and the American Foundation for the National Institutes of Health (FNIH) [52–55]. These guidelines suggest similar cutoffs for muscle mass, muscle strength, and physical performance for assessing and diagnosing sarcopenia [52].

In 2018, the Working Group (EWGSOP2) updated their initial definition of sarcopenia in order to take into account scientific and clinical evidence that came during the last 10 years. The new consensus (1) focuses on low muscle strength as a key characteristic of sarcopenia (cutoff points are: grip strength <27 kg for men and <16 kg for women and chair stand >15 s for five rises for both sexes), uses detection of low muscle quantity and to confirm the sarcopenia diagnosis (cutoff points are: appendicular skeletal muscle mass <20 kg for men and <15 kg for women), and identifies poor physical performance as indicative of severe sarcopenia (cutoff points are: gait speed \leq 0.8 m/s); (2) updates the clinical algorithm that is utilized for sarcopenia case-finding, diagnosis and confirmation, and severity determination to (3) provide distinct cutoff points for measurements of indicators that identify and define sarcopenia [56].

The most accurate methods for assessing muscle mass in clinical settings are bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA), which is considered the gold standard, because of its accuracy, wide availability, and also because it is the only radiological tool with accepted cutoff values to diagnose sarcopenia [57,58]. There is evidence that measuring muscle mass through deuterated creatine (D3Cr) can reliably measure muscle mass otherwise obtained through DXA, and correlate better with physical activity [59,60]. In research settings, the EWGSOP2 advises the use of magnetic resonance imaging (MRI) and computed tomography (CT) as well as DXA [56].

Because of the variety of assessment techniques, cutoff points, and sarcopenia criteria, sarcopenia diagnosis can be difficult to understand. In addition, the significant variations in the prevalence of sarcopenia relative to the studied population (community dwelling, hospitalization, and living in nursing homes) make it much more difficult to develop preventive routines and therapeutic protocols and involve a more person-centered and focused approach [61].

4. Epidemiology and Prevalence

As mentioned above, a recent systematic review and meta-analysis with data from 35 articles and 58,404 individuals around the world estimated that the overall prevalence of sarcopenia was 10% both in men and women aged over 60 [62]. Table 1 details the results of several epidemiologic studies assessing the prevalence of sarcopenia using different methods.

In a systematic review and meta-analysis conducted by our laboratory in 2019 with data of 41 studies and a total of 34,955 participants, we concluded that the prevalence of sarcopenia in community-dwelling individuals was 11% in men and 9% in women. The prevalence of sarcopenia in nursing-home older adults was 51% in men and 31% in women, whereas among hospitalized individuals it was found to be 23% and 24% for men and women, respectively [61].

An FNIH study of over 4900 patients \geq 60 years old found the mean age of sarcopenic patients to be 70.5 years among males and 71.6 years among females [63]. Sarcopenia appears to be more common

in individuals from non-Asian countries than in Asian individuals. Some of the main factors of this variability are body size, cultural background, ethnic characteristics, diet, and life quality. Moreover, the cutoff points for the Asian populations are lesser than those for the non-Asian individuals in both genders, having young people of the respective ethnic group as reference [11,62].

Moreover, it is recognized that the use of BIA as a way of calculating muscle mass underestimates fat mass and overestimates muscle mass [64]. The prevalence of sarcopenia based on the BIA in various studies was higher than that in the dual-energy X-ray absorptiometry (DXA)-based approach [65].

One systematic review and meta-analysis published in 2018 found that the prevalence of sarcopenia in nursing homes is 41% [66], which is four times higher than the prevalence in community dwelling individuals [62]. Table 1 shows the differences in the prevalence of sarcopenia according to the assessment method (DXA and BIA) and the population among various studies over the world.

Table 1. Differences in the prevalence of sarcopenia according to the assessment method used and the population studied.

First Author	Country	Population	Criteria	Muscle Mass Assessment Method	Sample (N)	Prevalence (% <i>, n</i>)
Rossi [67]	IT	Community dwelling	EWGSOP	DXA	274	33%, <i>n</i> = 92
Silva Neto [68]	BR	Community dwelling	EWGSOP	DXA	70	10%, <i>n</i> = 7
Hai [69]	CN	Community dwelling	AWGS	BIA	834	11%, <i>n</i> = 88
Yu [22]	CN	Community dwelling	EWGSOP	DXA	4000	5%, <i>n</i> = 216
Dodds [70]	GB	Community dwelling	EWGSOP	BIA	719	21%, <i>n</i> = 149
Yang [55]	CN	Community dwelling	AWGS	BIA	384	16%, <i>n</i> = 61
Lera [54]	CL	Community dwelling	EWGSOP	DXA	1006	19%, <i>n</i> = 192
Zengin [71]	GM	Community dwelling	EWGSOP	DXA	486	12%, <i>n</i> = 59
Bianchi [72]	IT	Hospitalized	EWGSOP	BIA	655	35%, <i>n</i> = 227
Smoliner [73]	DE	Hospitalized	EWGSOP	BIA	198	25%, <i>n</i> = 50
Martone [74]	IT	Hospitalized	EWGSOP	BIA	394	15%, <i>n</i> = 58
Cerri [75]	IT	Hospitalized	EWGSOP	BIA	103	21%, <i>n</i> = 22
Buckinx [76]	BE	Nursing home	EWGSOP	BIA	662	38%, <i>n</i> = 252
Senior [3]	AU	Nursing home	EWGSOP	BIA	102	40%, <i>n</i> = 41
Liu [77]	CN	Community dwelling	AWGS	BIA	4500	19%, <i>n</i> = 869
Sobestiansky [78] ⁿ	GB	Community dwelling		BIA	287	
1			EWGSOP			21%, <i>n</i> = 60
2			EWGSOP2			20%, <i>n</i> = 58
3			FNIH			8%, <i>n</i> = 24

AWGS, Asian Working Group for Sarcopenia; BIA, bioelectrical impedance analysis; DXA, dual-energy X-ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People. ⁿ Consists of different methods or definition for estimation of prevalence of sarcopenia.

5. Management of Sarcopenia in Older People

Several studies indicate that muscle function in older sarcopenic adults can be balanced and even enhanced by physical exercise, as seen in Table 2, specifically resistance training. However, providing suitable exercises for bed-rested older adults is especially challenging due to underlying comorbidities, which restrict the availability of energy for exercise, and a restricted dietary regime of low-quality

protein supply that exacerbates this issue further [22]. In contrast, community dwelling individuals are more physically active and have a better dietary regimen [79,80].

Sarcopenic individuals in nursing homes reported more sedentary activities, were less likely to report being currently physically active, and were also more likely to be malnourished [3,70,81].

Hence, there are additional risk factors for sarcopenia and functional decline in hospitalized individuals, because of reduced energy intake, low physical activity or prolonged bed-rest, depressed mood, and social isolation [82,83].

Community-dwelling individuals are more likely to be sarcopenic in situations where they are less physically active and lack good nutritional status [22,68,84–86]. Given the contemporary financial problems added to the age-related nutritional issues of older adults [21,87,88], attaining a good nutritional status becomes pivotal during older age.

5.1. Physical Activity and Exercise

5.1.1. Resistance Training

The most studied method of exercise therapy is progressive resistance training (PRT) where participants exercise against an increasing load. As an established treatment for muscle atrophy, resistance training, is known to reduce hospital length of stay and increase muscle cross-sectional area and grip strength in older adult populations [89,90]. Hip replacement due to primary hip osteoarthritis in patients aged 60–86 who did resistance training for the quadriceps muscle of the operated leg 2–3 times per week for 3–6 months had better outcomes than the standard rehabilitation regime patients [89]. A study by Liu et al. researching resistance training in adults with sarcopenia demonstrated the trouble that sarcopenic patients may have with resistance exercises by showing that there is no statistical difference in the Short Physical Performance Battery or 12 month gait pace relative to a non-resistance training control group [91].

Many studies have shown that isokinetic strength in an older adult population is improved by resistance training [92]. A large meta-analysis that investigated the relationship between physical exercise and muscle strength in a middle-aged population (40–65 years) has shown that resistance training has a greater impact on grip strength than other types of physical exercise [93].

Another plausible mode of resistance training is eccentric exercise. In this type of exercise, the muscle contracts while stretching itself (for instance during stairs descent). This form of muscle work has the advantage of increasing muscle strength with a reduced energy consumption and is suitable for energy-limited individuals due to the high-power and low-energy demands of eccentric contractions [94,95].

In their systematic review in 2019, Beckwée et al. stated that a high-intensity resistance training program is the best exercise for sarcopenic patients, but low-intensity resistance training may be sufficient to induce strength gains. Additionally, they recommend the following training parameters: 1–4 sets of 8–15 repetitions during 2–3 training moments a week [96].

5.1.2. Aerobic Exercise

Aerobic exercise of the skeletal muscle induces adenosine triphosphate (ATP) production in the mitochondria and enhances aerobic ability, metabolic control, and cardiovascular function. It also contributes to the activation of mitochondrial biogenesis and dynamics and to the restoration of mitochondrial metabolism, decreases catabolic gene expression, and increases the synthesis of muscle proteins [97–99]. Various studies demonstrated that aerobic exercise controls myostatin expression in mRNA [100]. Given that age-related sarcopenia is associated with these molecular factors, aerobic exercise tends to have a protective effect. Harber et al. recorded that cycle exercise in both 20-year-old and 74-year-old subjects improved muscle size and strength [101]. In addition, Bori et al. confirmed that older subjects had improved mitochondrial biogenesis and mitochondrial fission protein (Fis 1)

after 12 weeks of aerobic exercise training [102]. Collectively, aerobic exercise tends to ameliorate problems associated with mitochondria and improve muscle hypertrophy and strength.

5.1.3. High-Intensity Interval Training (HIIT)

High-intensity interval training (HIIT) modalities provide intense cycles alternated with periods of reduced intensity for rehabilitation, offering physiological benefits in less time than conventional exercise regimens [103]. The physiological changes due to HIIT may be partly regulated by signaling pathways that are usually associated with endurance training. This is confirmed by the significant increase in the peroxisome proliferator-activated receptor- γ coactivator 1 α (PGC-1 α ; i.e., the master regulator of mitochondrial biogenesis in the muscle) following HIIT [104]. The increase in PGC-1 α further highlights HIIT's possible widespread health benefits given the positive effects of an increase in PGC-1 α on oxidative efficiency, glucose absorption, antioxidant protection, and sarcopenia [104]. A study by Seldeen et al. showed that a 10 minute, 3 times a week, 4 month progressive HIIT protocol improves frailty status in aged mice with physical performance changes across multiple domains (strength, endurance, gait speed) [105]. A randomized controlled trial by Sculthorpe et al. investigating the efficacy of a low-frequency HIIT (LfHIIT) intervention on peak muscle power (peak power output (PPO)), body composition, and balance in lifelong sedentary but otherwise healthy males showed that 6 weeks of LfHIIT (one session every 5 days) were effective to induce clinically relevant improvements in absolute and relative PPO, but did not improve their static balance [106]. Moreover, when two maximal-intensity isokinetic eccentric resistance HIIT sessions were performed by aged individuals, they have shown that the elderly may participate in various physical activities, even high-intensity muscle-damaging activities, without a negative impact on muscle function and adaptation [107]. The previous finding is of importance, since it seems that eccentric training can induce health-promoting effects that may improve quality of life in elderly individuals [108].

5.1.4. Multimodal Exercise

No particular form of exercise appears to sufficiently meet the criteria for therapeutic exercise in age-related sarcopenia and thus well-rounded aerobic and resistance exercise programs are recommended [109]. Multimodal exercise includes a mix of strength training, cycling, aerobic training, equilibrium training, and other activities. Lee et al. reported that 12 weeks of a circuit program improved walking and balance skills and muscle isokinetic functions [110]. Two systematic studies identified important effects of multimodal exercise programs on all sarcopenia subdimensions in stable older adults [111,112]. Furthermore, Liberman et al. also discussed the impact on vulnerable older adults and concluded that after various forms of workouts, both muscle strength and physical functionality can be enhanced [111].

5.1.5. Whole-Body Vibration Therapy

In case of inability to exercise, passive exercise can be used in sarcopenia patients. Whole-body vibration therapy (WBV) in older adults has been shown to vastly improve various physical measures, including but not limited to leg isometric strength, knee dynamic strength, sit-to-stand performance, and jumping height [113]. Postmenopausal women saw increases in trunk and leg flexion strength only when combining strength and aerobic exercises with WBV [113]. Medium frequency and duration exercises appear most effective, with intervals at 40 Hz for 360 s significantly improving isokinetic knee extension in older adults [113,114]. In addition to this, a 12 week WBV in older adults can improve skeletal muscle mass, physical fitness, as well as quality of life [115]. However, long-term use of WBV is not suggested, as side effects such as spinal degeneration and increased serum testosterone and growth hormone can occur. Thus, safe protocols should be applied, when using WBV [116].

Table 2. Impact of resistance training, aerobic training, and whole-body vibrational therapy in sarcopenia.

First Author	Population	Interventions	Regimen	Observed Outcomes
Suetta [89]	Older, hip-surgery patients	Resistance training	3 times/week, for 12 weeks	↓ hospital length of stay, ↑ muscle strength and muscle cross-sectional area compared to the controls
Hassan [90]	Nursing care facility residents	Resistance training	2 times/week, for 24 weeks	↑ grip strength versus control group
Geirsdottir et al. [117]	Elder adults	Resistance training	RE + LTPA: 12 weeks + 16–18 months	↑ Quadriceps strength (only RE) ↑ Timed up-and-go performance (RE + LTPA)
Liu [91]	Sarcopenic adults	Resistance training	3 times/week, for 1–8 weeks	No difference compared to the non-training controls at 12 months
Chen et al. [118]	Sarcopenic obese adults	Aerobic training	Dance, 60 min for 8 weeks	↑ Muscle mass ↑ Back extensor strength
Harber et al. [101]	Young and older men	Aerobic training	Cycle ergometer, 12 weeks, 20–45 min, 3–4 day/week, 60%–80% of HRR	↑ Quadriceps volume (−6%) ↑ Muscle size ↑ Aerobic capacity
Lau [119]	Older adults	Whole-body vibrational therapy	1–7 sessions/week, for 6 weeks to 18 months	↑ muscle strength, improved jumping height and sit-to-stand performance
Candow [120]	Older adults	Resistance training with creatine supplementation	5–20 g/day, for 12–24 weeks	↑ muscle mass, chair rise performance, and knee extension strength

↑, increase; ↓, decrease; =, no change; HRR, heart rate reserve; RE, resistance exercise; LTPA, leisure-time physical activity.

5.2. Diet and Supplementation

Although diet plays an important role on sarcopenia and its management, dietary interventions are not as well studied as resistance training's proven role. As shown in Table 3, there is a large array of evidence that many dietary aspects may be important to the development of sarcopenia [71]. Food intake declines by about 25% from 40–70 years of age, and even more so when combined with a dietary pattern that could be characterized as monotonous, this may lead to insufficient nutrient intake. In sarcopenia, three areas were considered essential in terms of diet: vitamin D, calcium, and antioxidants.

Protein provides amino acids required for muscle synthesis. There is also evidence that the amino acid leucine may activate the signaling pathways leading to protein synthesis [71]. Considering leucine, findings in older people show that a high proportion of leucine was required in an essential amino acid mixture, in order to reverse the suboptimal muscle protein synthesis [121]. Skeletal muscle synthesis of aged mice was promoted by leucine-enriched whey protein supplements but not by isolated leucine [122]. In fact, for older men, 2.5 g of crystalline leucine co-ingestion with pure dietary protein could increase anabolic response [123]. In healthy older subjects, supplementation of β -hydroxy- β -methylbutyrate (HMB), a leucine metabolite, during 10 days of bed rest could preserve muscle mass [124]. However, a study in relatively young and healthy men (mean age 71) failed to show effect on strength or muscle mass, yet this may be due to the fact that the diet of the participants was low in leucine [71].

There is also a general concern that muscle production following a protein load may be blunted in older people [72], leading to the possibility that overall recommended protein intakes should be increased for older people. Observational evidence shows a strong correlation between protein intake and lean mass [72]. In aging, inflammation, and disease a higher dose of protein is needed to maximize muscle protein synthesis [125]. A dose of 1–1.2 g/kg body weight/day is considered to be optimal [126]. However, the literature suggests that protein consumption in amounts greater than the recommended daily allowance (RDA) can improve muscle strength and mass among older adults [127].

High-quality protein from whole foods, as well as dietary supplements providing isolated proteins, such as whey, casein, egg, meat, and soy increase accretion of postprandial protein and induce muscle protein synthesis [128].

In middle-aged and older adults, the impact of an egg-based and a cereal-based isocaloric and isonitrogenous breakfast was tested regarding whole-body protein synthesis, breakdown, and net balance. The egg-based breakfast intake resulted in a greater protein net balance, suppressing protein breakdown, while higher levels of essential amino-acids remained elevated, even after a standardized lunch, despite no difference in muscle protein synthesis [129].

Dairy is also a great protein source [130], and studies show a benefit in the elderly, concerning muscle mass and function. More to the point, the observational study by Radavelli-Bagatini [131,132] found a positive association between higher dairy intake and appendicular bone mineralization and muscle mass in elderly women, as well as greater whole-body lean mass and better physical performance. Dairy intake was measured via a food frequency questionnaire, body composition via dual-energy X-ray absorptiometry, and physical performance using hand-grip strength and timed up-and-go tests.

When comparing whey, casein, and casein hydrolysate, whey was found to be more effective in postprandial muscle protein accretion due to its faster digestion and absorption kinetics and its amino acid content and especially leucine [128]. Leucine ingestion can induce a reduction of urinary nitrogen loss. However, further research is needed [133,134]. Two studies from the same research group reported that, in young and older individuals, the ingestion of casein, which is slowly digested progressive or during sleep, intra-gastrically [135], could simulate muscle protein synthesis (MPS) nocturnally through hyperaminoacidemia and could even facilitate protein balance throughout post-exercise overnight recovery. Ingestion of 20 g of high-quality protein, equivalent to 20 g essential amino acids is optimal to stimulate rise in rates of MPS in older muscle [136].

A Cochrane review [72], however, found no clear impact of supplements on sarcopenia-related functional tests. Therefore, the quantity and composition of the dietary protein required to prevent and treat sarcopenia remains uncertain.

The timing of protein intake also plays a critical role in muscle synthesis, given the fact that, each meal allows accretion of protein for 2 to 4 hours. Increasing meal frequency and adequate evenly spaced protein intake across meals results in maximal protein anabolism during a long period of the day through postprandial protein accretion [136]. According to Mamerow [137], the 24 h muscle synthesis rate was 25% higher in healthy women and men when their protein intake was evenly distributed across meals, compared to isoenergetic and isonitrogenous diets with uneven protein distribution across meals. Protein-rich drinks consumed 2 hours after dinner, 30 minutes before sleep benefit MPS, muscle recovery, and overall metabolism both in the short and the long term. Furthermore, 30–40 g of casein protein ingested 30 minutes before sleep or via nasogastric tube increased overnight MPS in both young and older men, respectively [138].

The role of vitamin D in the pathophysiology of several diseases has also been highlighted lately [139]. For sarcopenia in particular, low vitamin D levels have been suggested to reduce skeletal muscle mass, leading to the development of sarcopenia [140]. More recently [141], fish intake has been reported to delay the onset of sarcopenia, due to its high protein, vitamin D and E, magnesium, and omega-3 content. Vitamin D polymorphisms were associated with muscle strength [142]; frailty (a disorder with some sarcopenia overlap) was also associated with vitamin D deficiency [143].

A study in women with post-stroke hemiplegia, who were followed for two years and were treated with vitamin D supplements, showed increases in type II muscle fibers and muscle strength as well as reduction in falls and hip fractures, in comparison to control group, suggesting improvements in atrophy [144]. Another systematic review and meta-analysis by Beaudart et al. studying various populations found improvements in muscle strength, particularly in ages >65 years old, with vitamin D supplementation of 400–4000 IU/day, for 1–60 months [145]. Muscle biopsies, however, could possibly determine more accurately the change in number and size of muscle fibers after vitamin D treatment.

Referring to protein supplementation, intervention studies of the impact of vitamin D on strength and physical performance have shown mixed results but, given that vitamin D deficiency is prevalent in the elderly, further studies are needed to determine its function in sarcopenia [146].

The cohort of InCHIANTI related the relationship between antioxidants in the composition of the body, with β -carotene and vitamin C being positively linked to the skeletal muscle mass [147]. β -carotene, especially, protects against the natural tendency to decrease in gait speed [148]. One of the best sources of omega-3 fatty acids is fatty fish. The Hertfordshire study found that grip strength improved by 0.48 kg in females and by 0.43 kg in males for every portion of fatty fish eaten. This outcome was further confirmed by an 8 week, randomized controlled trial of omega-3 supplementation in older adults, which recorded an increased rate of synthesis of muscle protein in the supplement group [149].

Concerning antioxidants, there is limited evidence for curcumin and bromelain's role in decreasing inflammation [150,151]. In fact, curcumin supplementation, in the form of the bio-available Meriva supplement (1 tablet/day) added to a diet and exercise plan, can help improve strength and physical performance in healthy older adults with loss of strength and tiredness, either alone or in conjunction with other dietary supplements [152].

Furthermore, resveratrol in conjunction with exercise increased mitochondrial density and decreased muscle fatigue resistance in older subjects aged 65–80 years old. In fact, the authors stated that resveratrol could reverse sarcopenia better than exercise alone, by increased muscle fiber size and power [153].

The combination of dietary interventions and exercise may lead to better results in the management of sarcopenia [154].

Table 3. Impact of nutrition and supplementation in sarcopenia.

First Author	Population	Interventions	Treatment Duration	Observed Outcomes
Abe [155]	Older nursing home residents	Group 1: EAAs (3 g), vit-D (800 IU), medium-chain TGs (6 g); Group 2: EAAs (3 g), vit-D (800 IU), or long-chain TGs (6 g)	13 weeks	↑ muscle strength, ↑ walking speed
Bauer [156]	Older community-dwelling individuals	Whey protein (40 g), carbohydrates (18 g), fat (6 g), vit-D (1600 IU), and mixture of vitamins, minerals, and fibers	13 weeks	↑ lean mass, = muscle strength, = walking speed
Evans [157]	Older community-dwelling individuals	Group 1: Leucine (2 g), L-Carnitine (1.5 g), creatine monohydrates (3 g), Vit-D (400 IU); Group 2: L-Carnitine (1.5 g)	8 weeks	↑ lean mass (only in group 1), = muscle strength
Ispoglou [158]	Older community-dwelling individuals	Group 1: EAA mixture (15 g); Group 2: EAA mixture leucine-enriched (15 g)	13 weeks	↑ lean mass (only in group 2), = muscle strength
Leenders [159]	Diabetes mellitus type 2 older individuals	Leucine	24 weeks	= lean mass, = muscle strength
Verlaan [160]	Older community-dwelling individuals	Whey protein (20 g), Vit-D (800 IU)	13 weeks	↑ lean mass
Radavelli-Bagatini [132]	Older community-dwelling women	Group 1: Dairy (≥ 2.2 servings/day) Group 2: Dairy (≤ 1.5 servings/day)	3 months	In comparison with group 2, group 1 had: ↑ whole-body lean mass, ↑ ASMM, ↑ hand-grip strength
Alemán-Mateo [161]	Older healthy individuals	210 g of ricotta cheese/day	12 weeks	↑ ASMM
Dal Negro [162]	Older community-dwelling individuals. COPD patients.	EAA (8 g)	12 weeks	↑ muscle strength, = lean mass

↑, increase; ↓, decrease; =, no change; EAA, essential amino-acid; TG, triglyceride; COPD, chronic obstructive pulmonary disease; ASMM, appendicular skeletal muscle mass.

5.3. Medication

Pharmacotherapy is a beneficial tool for treating sarcopenia for older people where exercise and dietary treatments are not effective methods of treating sarcopenia, where underlying co-morbidities can influence the supply of energy or digestive processes (e.g., in cancer cachexia). This is partly derived from the fact that a lot of older people may be unwilling or unable to do resistance training at the intensity required for it to be effective.

Hormone administration is a particularly explored therapy for sarcopenia. Growth hormone has been shown to cause an increase in muscle mass [163]. Furthermore, its implementation has not explicitly altered functional results and is therefore of questionable value. This highlights the difficulties of choosing outcome measure(s) for sarcopenia trials [164]. Testosterone supplementation has been shown to increase both muscle mass and strength in men but is also related to adverse cardiovascular conditions [165].

The fresh field of concern is drugs influencing the renin–angiotensin system, and whether the respective drugs may have direct muscle effects. An observational study initially indicated that inhibitors of ACE (angiotensin converting enzyme) could be beneficial to physical function [166], this result was subsequently verified in a trial showing increased walking time of six minutes in those given perindopril [167]. A similar impact was not apparent in a spironolactone trial [168], and neither of these medications has yet demonstrated any benefit in terms of results more commonly associated with sarcopenia.

Owing to their tissue selectivity, selective androgen receptor modulators (SARMs) are of particular interest. It is hoped that androgenic signaling will produce improvements in skeletal muscle mass and strength without dose-adverse effects with these drugs [169]. Myostatin, thalidomide, OHR/AVR118, celecoxib, VT-122, and anabolic agents such as ghrelin and its analogues, MT-102, BYM338, and ruxolitinib, are other compounds under investigation as sarcopenia therapies. In a phase 2 clinical trial for the treatment of cachexia in late-stage cancer patients, MT-102, the first-in-class anabolic catabolic transforming agent (ACTA), was recently tested. Test results indicated substantial increases in body weight in patients treated with 10 mg MT-102 twice daily over the test span of 16 weeks compared to substantial decreases in body weight in patients receiving placebo treatment [170]. MT-102 has been demonstrated to reverse sarcopenia in aged animal models [171]. More work is currently ongoing on MT-102 as a therapy for sarcopenia.

To date, few sarcopenia pharmacotherapies have been attempted after phase 2 trials. Growth-promoting agents (including myostatin inhibitors, testosterone, and SARMs) have the potential to boost lean mass in older people but converting these benefits to clinically applicable muscle strength and physical activity changes needs further assessment [172].

The next generation of medications to enhance physical function would possibly specifically target muscle function, with little to no effect on muscle mass, which would match well with the sarcopenia-based diagnosis criteria based on strength and patient performance [173].

6. Impact on the Quality of Life

Sarcopenia is associated with multiple adverse outcomes such as comorbidities, physical disability, poor physical performance, depression, frequent falls and increased hospitalization, functional decline, and increased mortality [3]. As such, older sarcopenic individuals tend to experience a lower quality of life (QoL), mainly because of their decreased physical function ability. Clinicians must frequently provide older people with questionnaires assessing their QoL, in order to better understand their needs, prioritize their problems, facilitate patient–doctor communication and track changes, or response to the treatment received. Accordingly, there is an increasing need for the use of the appropriate QoL measures in clinical practice, so clinicians can focus on treating the patients and not the just the disease [174].

7. Conclusions

As the global population ages, the prevalence of muscle wastage relative to age will increase. Following a universal standardized diagnosis will assist the discovery of viable treatment options. Malnutrition and low physical activity seem to be the two major factors associated with sarcopenia. Individual targeted therapies including supplementation and diet could be very beneficial for sarcopenic individuals. However, there are no currently approved medical therapies for the treatment of sarcopenia. The increase of awareness and understanding of this disease is essential for the continued development of standardized treatment, as well as diagnostic options, which will in turn lead to better care and quality of life for our geriatric populations. An appropriate exercise regimen, accompanied by nutritional interventions should be of major importance for a better outcome of sarcopenic and geriatric patients.

Funding: This research received no external funding.

Conflicts of Interest: The author declares no conflicts of interest.

References

1. Traub, J.; Bergheim, I.; Eibisberger, M.; Stadlbauer, V. Sarcopenia and Liver Cirrhosis—Comparison of the European Working Group on Sarcopenia Criteria 2010 and 2019. *Nutrients* **2020**, *12*, 547. [[CrossRef](#)] [[PubMed](#)]
2. Rosenberg, I.H. Sarcopenia: Origins and Clinical Relevance. *J. Nutr.* **1997**, *127*, 990S–991S. [[CrossRef](#)] [[PubMed](#)]
3. Senior, H.E.; Henwood, T.R.; Beller, E.M.; Mitchell, G.K.; Keogh, J.W.L.L. Prevalence and risk factors of sarcopenia among adults living in nursing homes. *Maturitas* **2015**, *82*, 418–423. [[CrossRef](#)] [[PubMed](#)]
4. Santilli, V.; Bernetti, A.; Mangone, M.; Paoloni, M. Clinical definition of sarcopenia. *Clin. Cases Miner. Bone Metab.* **2014**, *11*, 177–180. [[CrossRef](#)]
5. Sinclair, A.J.; Abdelhafiz, A.H.; Rodriguez-Manas, L. Frailty and sarcopenia—Newly emerging and high impact complications of diabetes. *J. Diabetes Complicat.* **2017**, *31*, 1465–1473. [[CrossRef](#)]
6. Peterson, S.J.; Mozer, M. Differentiating Sarcopenia and Cachexia Among Patients with Cancer. *Nutr. Clin. Pract.* **2017**, *32*, 30–39. [[CrossRef](#)]
7. Bonato, M.; Turrini, F.; Galli, L.; Banfi, G.; Cinque, P. The role of physical activity for the management of sarcopenia in people living with HIV. *Int. J. Environ. Res. Public Health* **2020**, *17*, 1283. [[CrossRef](#)]
8. Beaudart, C.; McCloskey, E.E.; Bruyere, O.; Cesari, M.; Rolland, Y.; Rizzoli, R.R.; Araujo de Carvalho, I.I.; Amuthavalli Thiyagarajan, J.; Bautmans, I.; Bertiere, M.-C.; et al. Sarcopenia in daily practice: Assessment and management. *BMC Geriatr.* **2016**, *16*, 170. [[CrossRef](#)]
9. Laviano, A.; Gori, C.; Rianda, S. Sarcopenia and nutrition. *Adv. Food Nutr. Res.* **2014**, *71*, 101–136.
10. Hashemi, R.; Shafiee, G.; Motlagh, A.D.; Pasalar, P.; Esmailzadeh, A.; Siassi, F.; Larijani, B.; Heshmat, R. Sarcopenia and its associated factors in Iranian older individuals: Results of SARIR study. *Arch. Gerontol. Geriatr.* **2016**, *66*, 18–22. [[CrossRef](#)]
11. Lee, J.S.W.W.; Auyeung, T.; Kwok, T.; Lau, E.M.C.C.; Leung, P.; Woo, J. Associated Factors and Health Impact of Sarcopenia in Older Chinese Men and Women: A Cross-Sectional Study. *Gerontology* **2007**, *53*, 404–410. [[CrossRef](#)] [[PubMed](#)]
12. Marty, E.; Liu, Y.; Samuel, A.; Or, O.; Lane, J. A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease. *Bone* **2017**, *105*, 276–286. [[CrossRef](#)] [[PubMed](#)]
13. Ryall, J.G.; Schertzer, J.D.; Lynch, G.S. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. *Biogerontology* **2008**, *9*, 213–228. [[CrossRef](#)] [[PubMed](#)]
14. Riuuzzi, F.; Sorci, G.; Arcuri, C.; Giambanco, I.; Bellezza, I.; Minelli, A.; Donato, R. Cellular and molecular mechanisms of sarcopenia: The S100B perspective. *J. Cachexia. Sarcopenia Muscle* **2018**, *9*, 1255–1268. [[CrossRef](#)] [[PubMed](#)]
15. Faulkner, J.A.; Larkin, L.M.; Claffin, D.R.; Brooks, S.V. Age-related changes in the structure and function of skeletal muscles. *Clin. Exp. Pharmacol. Physiol.* **2007**, *34*, 1091–1096. [[CrossRef](#)] [[PubMed](#)]
16. Cruz-Jentoft, A.J.; Sayer, A.A. Sarcopenia. *Lancet* **2019**, *393*, 2636–2646. [[CrossRef](#)]
17. Marcell, T.J. Sarcopenia: Causes, Consequences, and Preventions. *J. Gerontol. Ser. A* **2003**, *58*, M911–M916. [[CrossRef](#)]

18. Doherty, T.J. Invited review: Aging and sarcopenia. *J. Appl. Physiol.* **2003**, *95*, 1717–1727. [[CrossRef](#)]
19. Evans, W.J.; Campbell, W.W. Sarcopenia and age-related changes in body composition and functional capacity. *J. Nutr.* **1993**, *123*, 465–468. [[CrossRef](#)]
20. Alexandre, T.; Duarte, Y.A.D.O.; Santos, J.; Wong, R.; Lebrao, M. Sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP) versus dynapenia as a risk factor for mortality in the elderly. *J. Nutr. Health Aging* **2014**, *18*, 751–756. [[CrossRef](#)]
21. Grammatikopoulou, M.G.; Gkiouras, K.; Theodoridis, X.; Tsisimiri, M.; Markaki, A.G.; Chourdakis, M.; Goulis, D.G. Food insecurity increases the risk of malnutrition among community-dwelling older adults. *Maturitas* **2019**, *119*, 8–13. [[CrossRef](#)] [[PubMed](#)]
22. Yu, R.; Wong, M.; Leung, J.; Lee, J.; Auyeung, T.W.; Woo, J. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community-dwelling older Chinese adults. *Geriatr. Gerontol. Int.* **2014**, *14*, 15–28. [[CrossRef](#)] [[PubMed](#)]
23. Tay, L.; Ding, Y.Y.; Leung, B.P.; Ismail, N.H.; Yeo, A.; Yew, S.; Tay, K.S.; Tan, C.H.; Chong, M.S. Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults. *Age (Omaha)* **2015**, *37*, 121. [[CrossRef](#)] [[PubMed](#)]
24. Volpato, S.; Bianchi, L.; Cherubini, A.; Landi, F.; Maggio, M.; Savino, E.; Bandinelli, S.; Ceda, G.P.; Guralnik, J.M.; Zuliani, G.; et al. Prevalence and clinical correlates of sarcopenia in community-dwelling older people: Application of the EWGSOP definition and diagnostic algorithm. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2014**, *69*, 438–446. [[CrossRef](#)]
25. Mishra, G.D.; Chung, H.-F.; Cano, A.; Chedraui, P.; Goulis, D.G.; Lopes, P.; Mueck, A.; Rees, M.; Senturk, L.M.; Simoncini, T.; et al. EMAS position statement: Predictors of premature and early natural menopause. *Maturitas* **2019**, *123*, 82–88. [[CrossRef](#)]
26. Anagnostis, P.; Siolos, P.; Gkekas, N.K.; Kosmidou, N.; Artzouchaltzi, A.-M.; Christou, K.; Paschou, S.A.; Potoupnis, M.; Kenanidis, E.; Tsiridis, E.; et al. Association between age at menopause and fracture risk: A systematic review and meta-analysis. *Endocrine* **2019**, *63*, 213–224. [[CrossRef](#)]
27. Proctor, M.J.; McMillan, D.C.; Horgan, P.G.; Fletcher, C.D.; Talwar, D.; Morrison, D.S. Systemic inflammation predicts all-cause mortality: A glasgow inflammation outcome study. *PLoS ONE* **2015**, *10*, e0116206. [[CrossRef](#)]
28. Monteiro, R.; Azevedo, I. Chronic inflammation in obesity and the metabolic syndrome. *Mediat. Inflamm.* **2010**. [[CrossRef](#)]
29. Beyer, I.; Mets, T.; Bautmans, I. Chronic low-grade inflammation and age-related sarcopenia. *Curr. Opin. Clin. Nutr. Metab. Care* **2012**, *15*, 12–22. [[CrossRef](#)]
30. De Martinis, M.; Franceschi, C.; Monti, D.; Ginaldi, L. Inflamm-aging and lifelong antigenic load as major determinants of ageing rate and longevity. *FEBS Lett.* **2005**, *579*, 2035–2039. [[CrossRef](#)]
31. Frasca, D.; Blomberg, B.B. Inflammaging decreases adaptive and innate immune responses in mice and humans. *Biogerontology* **2016**, *17*, 7–19. [[CrossRef](#)] [[PubMed](#)]
32. Cannizzo, E.S.; Clement, C.C.; Sahu, R.; Follo, C.; Santambrogio, L. Oxidative stress, inflamm-aging and immunosenescence. *J. Proteomics* **2011**, *74*, 2313–2323. [[CrossRef](#)] [[PubMed](#)]
33. Sansoni, P.; Vescovini, R.; Fagnoni, F.; Biasini, C.; Zanni, F.; Zanlari, L.; Telera, A.; Lucchini, G.; Passeri, G.; Monti, D.; et al. The immune system in extreme longevity. *Exp. Gerontol.* **2008**, *43*, 61–65. [[CrossRef](#)] [[PubMed](#)]
34. Maggio, M.; Guralnik, J.M.; Longo, D.L.; Ferrucci, L. Interleukin-6 in aging and chronic disease: A magnificent pathway. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2006**, *61*, 575–584. [[CrossRef](#)] [[PubMed](#)]
35. Thomas, D.R. Sarcopenia. *Clin. Geriatr. Med.* **2010**, *26*, 331–346. [[CrossRef](#)] [[PubMed](#)]
36. Mitch, W.E.; Goldberg, A.L. Mechanisms of disease: Mechanisms of muscle wasting: The role of the ubiquitin-proteasome pathway. *N. Engl. J. Med.* **1996**, *335*, 1897–1905. [[CrossRef](#)]
37. Ferrucci, L.; Harris, T.B.; Guralnik, J.M.; Tracy, R.P.; Corti, M.C.; Cohen, H.J.; Penninx, B.; Pahor, M.; Wallace, R.; Havlik, R.J. Serum IL-6 level and the development of disability in older persons. *J. Am. Geriatr. Soc.* **1999**, *47*, 639–646. [[CrossRef](#)]
38. Toth, M.J.; Ades, P.A.; Tischler, M.D.; Tracy, R.P.; LeWinter, M.M. Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. *Int. J. Cardiol.* **2006**, *109*, 179–187. [[CrossRef](#)]

39. Visser, M.; Pahor, M.; Taaffe, D.R.; Goodpaster, B.H.; Simonsick, E.M.; Newman, A.B.; Nevitt, M.; Harris, T.B. Relationship of interleukin-6 and tumor necrosis factor- α with muscle mass and muscle strength in elderly men and women: The health ABC study. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2002**, *57*, M326–M332. [[CrossRef](#)]
40. Haran, P.H.; Rivas, D.A.; Fielding, R.A. Role and potential mechanisms of anabolic resistance in sarcopenia. *J. Cachexia. Sarcopenia Muscle* **2012**, *3*, 157–162. [[CrossRef](#)]
41. Elkina, Y.; von Haehling, S.; Anker, S.D.; Springer, J. The role of myostatin in muscle wasting: An overview. *J. Cachexia. Sarcopenia Muscle* **2011**, *2*, 143–151. [[CrossRef](#)] [[PubMed](#)]
42. White, D.K.; Neogi, T.; Nevitt, M.C.; Peloquin, C.E.; Zhu, Y.; Boudreau, R.M.; Cauley, J.A.; Ferrucci, L.; Harris, T.B.; Satterfield, S.M.; et al. Trajectories of gait speed predict mortality in well-functioning older adults: The health, aging and body composition study. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2013**, *68*, 456–464. [[CrossRef](#)] [[PubMed](#)]
43. Waters, D.L.; Baumgartner, R.N. Sarcopenia and obesity. *Clin. Geriatr. Med.* **2011**, *27*, 401–421. [[CrossRef](#)] [[PubMed](#)]
44. Kalyani, R.R.; Corriere, M.; Ferrucci, L. Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases. *Lancet Diabetes Endocrinol.* **2014**, *2*, 819–829. [[CrossRef](#)]
45. White, T.A.; Lebrasseur, N.K. Myostatin and sarcopenia: Opportunities and challenges—A mini-review. *Gerontology* **2014**, *60*, 289–293. [[CrossRef](#)]
46. Vitale, J.A.; Bonato, M.; La Torre, A.; Banfi, G. The role of the molecular clock in promoting skeletal muscle growth and protecting against sarcopenia. *Int. J. Mol. Sci.* **2019**, *20*, 4318. [[CrossRef](#)]
47. Lipton, J.O.; Yuan, E.D.; Boyle, L.M.; Ebrahimi-Fakhari, D.; Kwiatkowski, E.; Nathan, A.; Güttler, T.; Davis, F.; Asara, J.M.; Sahin, M. The circadian protein BMAL1 regulates translation in response to S6K1-mediated phosphorylation. *Cell* **2015**, *161*, 1138–1151. [[CrossRef](#)]
48. Dhillon, R.J.; Hasni, S. Pathogenesis and Management of Sarcopenia. *Clin. Geriatr. Med.* **2017**, *33*, 17–26. [[CrossRef](#)]
49. Sayer, A.A.; Syddall, H.E.; Gilbody, H.J.; Dennison, E.M.; Cooper, C. Does sarcopenia originate in early life? Findings from the Hertfordshire cohort study. *J. Gerontol. A Biol. Sci. Med. Sci.* **2004**, *59*, M930–M934. [[CrossRef](#)]
50. Sayer, A.A.; Syddall, H.; Martin, H.; Patel, H.; Baylis, D.; Cooper, C. The developmental origins of sarcopenia. *J. Nutr. Health Aging* **2008**, *12*, 427–432. [[CrossRef](#)]
51. Patel, H.P.; Jameson, K.A.; Syddall, H.E.; Martin, H.J.; Stewart, C.E.; Cooper, C.; Sayer, A.A. Developmental influences, muscle morphology, and sarcopenia in community-dwelling older men. *J. Gerontol. A Biol. Sci. Med. Sci.* **2012**, *67*, 82–87. [[CrossRef](#)] [[PubMed](#)]
52. Gao, L.; Jiang, J.; Yang, M.; Hao, Q.; Luo, L.; Dong, B. Prevalence of Sarcopenia and Associated Factors in Chinese Community-Dwelling Elderly: Comparison Between Rural and Urban Areas. *J. Am. Med. Dir. Assoc.* **2015**, *16*, 1003–e1. [[CrossRef](#)] [[PubMed](#)]
53. Patel, H.P.; Syddall, H.E.; Jameson, K.; Robinson, S.; Denison, H.; Roberts, H.C.; Edwards, M.; Dennison, E.; Cooper, C.; Aihie Sayer, A. Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: Findings from the Hertfordshire Cohort Study (HCS). *Age Ageing* **2013**, *42*, 378–384. [[CrossRef](#)] [[PubMed](#)]
54. Lera, L.; Albala, C.; Sánchez, H.; Angel, B.; Hormazabal, M.J.; Márquez, C.; Arroyo, P. Prevalence of Sarcopenia in Community-Dwelling Chilean Elders According to an Adapted Version of the European Working Group on Sarcopenia in Older People (EWGSOP) Criteria. *J. Frailty Aging* **2017**, *6*, 12–17. [[PubMed](#)]
55. Yang, M.; Hu, X.; Xie, L.; Zhang, L.; Zhou, J.; Lin, J.; Wang, Y.; Li, Y.Y.; Han, Z.; Zhang, D.; et al. Screening Sarcopenia in Community-Dwelling Older Adults: SARC-F vs SARC-F Combined with Calf Circumference (SARC-CalF). *J. Am. Med. Dir. Assoc.* **2018**, *19*, 277–e1. [[CrossRef](#)]
56. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyere, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Ageing* **2019**, *48*, 16–31. [[CrossRef](#)]
57. Bahat, G.; Tufan, A.; Kilic, C.; Karan, M.A.; Cruz-Jentoft, A.J. Prevalence of sarcopenia and its components in community-dwelling outpatient older adults and their relation with functionality. *Aging Male* **2018**, 1–7. [[CrossRef](#)]

58. Albano, D.; Messina, C.; Vitale, J.; Sconfienza, L.M. Imaging of sarcopenia: Old evidence and new insights. *Eur. Radiol.* **2019**, *30*, 2199–2208. [[CrossRef](#)]
59. Lee, S. Coresidence of older parents and adult children benefits older adults' psychological well-being: Path analysis. *Innov. Aging* **2019**, *3*, S324. [[CrossRef](#)]
60. Cawthon, P.M.; Orwoll, E.S.; Peters, K.E.; Ensrud, K.E.; Cauley, J.A.; Kado, D.M.; Stefanick, M.L.; Shikany, J.M.; Strotmeyer, E.S.; Glynn, N.W.; et al. Strong Relation Between Muscle Mass Determined by D3-creatine Dilution, Physical Performance, and Incidence of Falls and Mobility Limitations in a Prospective Cohort of Older Men. *J. Gerontol. A Biol. Sci. Med. Sci.* **2019**, *74*, 844–852. [[CrossRef](#)]
61. Papadopoulou, S.K.; Tsintavis, P.; Potsaki, G.; Papandreou, D. Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis. *J. Nutr. Health Aging* **2019**, *24*, 83–90. [[CrossRef](#)] [[PubMed](#)]
62. Shafiee, G.; Keshtkar, A.; Soltani, A.; Ahadi, Z.; Larijani, B.; Heshmat, R. Prevalence of sarcopenia in the world: A systematic review and meta- analysis of general population studies. *J. Diabetes Metab. Disord.* **2017**, *16*, 21. [[CrossRef](#)] [[PubMed](#)]
63. Batsis, J.A.; Mackenzie, T.A.; Lopez-Jimenez, F.; Bartels, S.J. Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National Health and Nutrition Examination Surveys 1999–2004. *Nutr. Res.* **2015**, *35*, 1031–1039. [[CrossRef](#)] [[PubMed](#)]
64. Jansen, W.J.; Ossenkoppele, R.; Knol, D.L.; Tijms, B.M.; Scheltens, P.; Verhey, F.R.J.; Visser, P.J.; Aalten, P.; Aarsland, D.; Alcolea, D.; et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. *JAMA* **2015**, *313*, 1924. [[CrossRef](#)] [[PubMed](#)]
65. Chien, M.-Y.; Huang, T.-Y.; Wu, Y.-T. Prevalence of Sarcopenia Estimated Using a Bioelectrical Impedance Analysis Prediction Equation in Community-Dwelling Elderly People in Taiwan. *J. Am. Geriatr. Soc.* **2008**, *56*, 1710–1715. [[CrossRef](#)]
66. Shen, Y.; Chen, J.; Chen, X.; Hou, L.S.; Lin, X.; Yang, M. Prevalence and Associated Factors of Sarcopenia in Nursing Home Residents: A Systematic Review and Meta-analysis. *J. Am. Med. Dir. Assoc.* **2019**, *20*, 5–13. [[CrossRef](#)]
67. Rossi, A.P.; Micciolo, R.; Rubele, S.; Fantin, F.; Caliarì, C.; Zoico, E.; Mazzali, G.; Ferrari, E.; Volpato, S.; Zamboni, M. Assessing the risk of sarcopenia in the elderly: The Mini Sarcopenia Risk Assessment (MSRA) questionnaire. *J. Nutr. Health Aging* **2017**, *21*, 743–749. [[CrossRef](#)]
68. Silva Neto, L.S.; Karnikowski, M.G.O.; Osório, N.B.; Pereira, L.C.; Mendes, M.B.; Galato, D.; Matheus, L.B.G.; Matheus, J.P.C. Association between sarcopenia and quality of life in quilombola elderly in Brazil. *Int. J. Gen. Med.* **2016**, *9*, 89–97. [[CrossRef](#)]
69. Hai, S.; Wang, H.; Cao, L.; Liu, P.; Zhou, J.; Yang, Y.; Dong, B. Association between sarcopenia with lifestyle and family function among community-dwelling Chinese aged 60 years and older. *BMC Geriatr.* **2017**, *17*, 187. [[CrossRef](#)]
70. Dodds, R.M.; Granic, A.; Davies, K.; Kirkwood, T.B.L.L.; Jagger, C.; Sayer, A.A. Prevalence and incidence of sarcopenia in the very old: Findings from the Newcastle 85+ Study. *J. Cachexia. Sarcopenia Muscle* **2017**, *8*, 229–237. [[CrossRef](#)]
71. Zengin, A.; Jarjou, L.M.; Prentice, A.; Cooper, C.; Ebeling, P.R.; Ward, K.A. The prevalence of sarcopenia and relationships between muscle and bone in ageing West-African Gambian men and women. *J. Cachexia. Sarcopenia Muscle* **2018**, *9*, 920–928. [[CrossRef](#)] [[PubMed](#)]
72. Bianchi, L.; Ferrucci, L.; Cherubini, A.; Maggio, M.; Bandinelli, S.; Savino, E.; Brombo, G.; Zuliani, G.; Guralnik, J.M.; Landi, F.; et al. The Predictive Value of the EWGSOP Definition of Sarcopenia: Results from the InCHIANTI Study. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2015**, *71*, 259–264. [[CrossRef](#)] [[PubMed](#)]
73. Smoliner, C.; Sieber, C.C.; Wirth, R. Prevalence of Sarcopenia in Geriatric Hospitalized Patients. *J. Am. Med. Dir. Assoc.* **2014**, *15*, 267–272. [[CrossRef](#)]
74. Martone, A.M.; Bianchi, L.; Abete, P.; Bellelli, G.; Bo, M.; Cherubini, A.; Corica, F.; Di Bari, M.; Maggio, M.; Manca, G.M.; et al. The incidence of sarcopenia among hospitalized older patients: Results from the Glisten study. *J. Cachexia. Sarcopenia Muscle* **2017**, *8*, 907–914. [[CrossRef](#)]
75. Cerri, A.P.; Bellelli, G.; Mazzone, A.; Pittella, F.; Landi, F.; Zamboni, A.; Annoni, G. Sarcopenia and malnutrition in acutely ill hospitalized elderly: Prevalence and outcomes. *Clin. Nutr.* **2015**, *34*, 745–751. [[CrossRef](#)]

76. Buckinx, F.; Reginster, J.Y.; Bruenois, T.; Lenaerts, C.; Beudart, C.; Croisier, J.L.; Petermans, J.; Bruyère, O. Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: Results of the SENIOR cohort. *J. Musculoskelet. Neuronal Interact.* **2017**, *17*, 209–217.
77. Liu, X.; Hou, L.; Xia, X.; Liu, Y.; Zuo, Z.; Zhang, Y.; Zhao, W.; Hao, Q.; Yue, J.; Dong, B. Prevalence of sarcopenia in multi ethnics adults and the association with cognitive impairment: Findings from West-China health and aging trend study. *BMC Geriatr.* **2020**, *20*, 63. [[CrossRef](#)]
78. Sobestiansky, S.; Michaelsson, K.; Cederholm, T. Sarcopenia prevalence and associations with mortality and hospitalisation by various sarcopenia definitions in 85–89 year old community-dwelling men: A report from the ULSAM study. *BMC Geriatr.* **2019**, *19*, 318. [[CrossRef](#)]
79. Grammatikopoulou, M.G.; Papadopoulou, S.K.; Zakas, A.; Mylona, A.; Kapsalis, I. Dietary Intake of Free-Living Elderly in Northern Greece. *J. Nutr. Elder.* **2006**, *26*, 131–146. [[CrossRef](#)]
80. Papadopoulou, S.K.; Papadopoulou, S.D.; Zerva, A.; Paraskevas, G.; Dalkiranis, A.; Ioannou, I.; Fahantidou, A. Health status and socioeconomic factors as determinants of physical activity level in the elderly. *Med. Sci. Monit.* **2003**, *9*, CR79–CR83.
81. Yoo, J.I.; Ha, Y.C.; Lee, Y.K.; Yoo, M.J.; Koo, K.H. High prevalence of sarcopenia among binge drinking elderly women: A nationwide population-based study. *BMC Geriatr.* **2017**, *17*, 114. [[CrossRef](#)] [[PubMed](#)]
82. Wen, X.; An, P.; Chen, W.C.; Lv, Y.; Fu, Q. Comparisons of sarcopenia prevalence based on different diagnostic criteria in Chinese older adults. *J. Nutr. Health Aging* **2015**, *19*, 342–347. [[CrossRef](#)] [[PubMed](#)]
83. Wang, H.; Hai, S.; Cao, L.; Zhou, J.; Liu, P.; Dong, B.-R.R. Estimation of prevalence of sarcopenia by using a new bioelectrical impedance analysis in Chinese community-dwelling elderly people. *BMC Geriatr.* **2016**, *16*, 216. [[CrossRef](#)]
84. Beudart, C.; Reginster, J.Y.; Petermans, J.; Gillain, S.; Quabron, A.; Locquet, M.; Slomian, J.; Buckinx, F.; Bruyère, O. Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. *Exp. Gerontol.* **2015**, *69*, 103–110. [[CrossRef](#)]
85. Yoshida, D.; Suzuki, T.; Shimada, H.; Park, H.; Makizako, H.; Doi, T.; Anan, Y.; Tsutsumimoto, K.; Uemura, K.; Ito, T.; et al. Using two different algorithms to determine the prevalence of sarcopenia. *Geriatr. Gerontol. Int.* **2014**, *14*, 46–51. [[CrossRef](#)] [[PubMed](#)]
86. Legrand, D.; Vaes, B.; Matheï, C.; Swine, C.; Degryse, J.M. The prevalence of sarcopenia in very old individuals according to the european consensus definition: Insights from the belfrail study. *Age Ageing* **2013**, *42*, 727–734. [[CrossRef](#)]
87. Grammatikopoulou, M.; Metos, E.; Hassapidou, M.; Tsigga, M. Food Insecurity among elderly in Athens. *Clin. Nutr.* **2012**, *S7*, 46.
88. Pepa, A.; Apostolaki, I.; Magriplis, E.; Malisova, O.; Galanaki, C.; Chamos, A.; Grammatikopoulou, M.G.; Kapsokefalou, M. Social capital and health determine beverage variety among older adults: An asset-based approach. *Nutrients* **2020**, in press.
89. Suetta, C.; Magnusson, S.P.; Rosted, A.; Aagaard, P.; Jakobsen, A.K.; Larsen, L.H.; Duus, B.; Kjaer, M. Resistance training in the early postoperative phase reduces hospitalization and leads to muscle hypertrophy in elderly hip surgery patients—A controlled, randomized study. *J. Am. Geriatr. Soc.* **2004**, *52*, 2016–2022. [[CrossRef](#)]
90. Hassan, B.H.; Hewitt, J.; Keogh, J.W.L.; Bermeo, S.; Duque, G.; Henwood, T.R. Impact of resistance training on sarcopenia in nursing care facilities: A pilot study. *Geriatr. Nurs. (Minneap)* **2016**, *37*, 116–121. [[CrossRef](#)]
91. Liu, C.K.; Leng, X.; Hsu, F.-C.; Kritchevsky, S.B.; Ding, J.; Earnest, C.P.; Ferrucci, L.; Goodpaster, B.H.; Guralnik, J.M.; Lenchik, L.; et al. The impact of sarcopenia on a physical activity intervention: The lifestyle interventions and independence for elders pilot study (LIFE-P). *J. Nutr. Health Aging* **2013**, *18*, 59–64. [[CrossRef](#)] [[PubMed](#)]
92. Carvalho, J.; Marques, E.; Soares, J.M.C.; Mota, J. Isokinetic strength benefits after 24 weeks of multicomponent exercise training and combined exercise training in older adults. *Aging Clin. Exp. Res.* **2010**, *22*, 63–69. [[CrossRef](#)] [[PubMed](#)]
93. Ferreira, M.L.; Sherrington, C.; Smith, K.; Carswell, P.; Bell, R.; Bell, M.; Nascimento, D.P.; Máximo Pereira, L.S.; Vardon, P. Physical activity improves strength, balance and endurance in adults aged 40–65 years: A systematic review. *J. Physiother.* **2012**, *58*, 145–156. [[CrossRef](#)]
94. Trouwborst, I.; Verreijen, A.; Memelink, R.; Massanet, P.; Boirie, Y.; Weijjs, P.; Tieland, M. Exercise and nutrition strategies to counteract sarcopenic obesity. *Nutrients* **2018**, *10*, 605. [[CrossRef](#)] [[PubMed](#)]

95. Mueller, M.; Breil, F.A.; Vogt, M.; Steiner, R.; Lippuner, K.; Popp, A.; Klossner, S.; Hoppeler, H.; Dapp, C. Different response to eccentric and concentric training in older men and women. *Eur. J. Appl. Physiol.* **2009**, *107*, 145–153. [[CrossRef](#)] [[PubMed](#)]
96. Beckwée, D.; Delaere, A.; Aelbrecht, S.; Baert, V.; Beudart, C.; Bruyere, O.; de Saint-Hubert, M.; Bautmans, I. Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. *J. Nutr. Health Aging* **2019**, *23*, 494–502. [[CrossRef](#)]
97. Erlich, A.T.; Tryon, L.D.; Crilly, M.J.; Memme, J.M.; Moosavi, Z.S.M.; Oliveira, A.N.; Beyfuss, K.; Hood, D.A. Function of specialized regulatory proteins and signaling pathways in exercise-induced muscle mitochondrial biogenesis. *Integr. Med. Res.* **2016**, *5*, 187–197. [[CrossRef](#)]
98. Konopka, A.R.; Harber, M.P. Skeletal muscle hypertrophy after aerobic exercise training. *Exerc. Sport Sci. Rev.* **2014**, *42*, 53–61. [[CrossRef](#)]
99. Seo, D.Y.; Lee, S.R.; Kim, N.; Ko, K.S.; Rhee, B.D.; Han, J. Age-related changes in skeletal muscle mitochondria: The role of exercise. *Integr. Med. Res.* **2016**, *5*, 182–186. [[CrossRef](#)]
100. Ko, I.G.; Jeong, J.W.; Kim, Y.H.; Jee, Y.S.; Kim, S.E.; Kim, S.H.; Jin, J.J.; Kim, C.J.; Chung, K.J. Aerobic exercise affects myostatin expression in aged rat skeletal muscles: A possibility of antiaging effects of aerobic exercise related with pelvic floor muscle and urethral rhabdosphincter. *Int. Neurourol. J.* **2014**, *18*, 77. [[CrossRef](#)]
101. Harber, M.P.; Konopka, A.R.; Udem, M.K.; Hinkley, J.M.; Minchev, K.; Kaminsky, L.A.; Trappe, T.A.; Trappe, S. Aerobic exercise training induces skeletal muscle hypertrophy and age-dependent adaptations in myofiber function in young and older men. *J. Appl. Physiol.* **2012**, *113*, 1495–1504. [[CrossRef](#)]
102. Bori, Z.; Zhao, Z.; Koltai, E.; Fatouros, I.G.; Jamurtas, A.Z.; Douroudos, I.I.; Terzis, G.; Chatzinikolaou, A.; Sovatzidis, A.; Draganidis, D.; et al. The effects of aging, physical training, and a single bout of exercise on mitochondrial protein expression in human skeletal muscle. *Exp. Gerontol.* **2012**, *47*, 417–424. [[CrossRef](#)] [[PubMed](#)]
103. Gillen, J.B.; Gibala, M.J. Is high-intensity interval training a time-efficient exercise strategy to improve health and fitness? *Appl. Physiol. Nutr. Metab.* **2014**, *39*, 409–412. [[CrossRef](#)] [[PubMed](#)]
104. Gibala, M.J.; Little, J.P.; Macdonald, M.J.; Hawley, J.A. Physiological adaptations to low-volume, high-intensity interval training in health and disease. *J. Physiol.* **2012**, *590*, 1077–1084. [[CrossRef](#)] [[PubMed](#)]
105. Seldeen, K.L.; Lasky, G.; Leiker, M.M.; Pang, M.; Personius, K.E.; Troen, B.R. High Intensity Interval Training Improves Physical Performance and Frailty in Aged Mice. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2018**, *73*, 429–437. [[CrossRef](#)]
106. Herbert, P.; Grace, F.; Sculthorpe, N. One Session of High-Intensity Interval Training (HIIT) Every Five Days Improves Muscle Power in Lifelong Sedentary Ageing Men: A Randomized Controlled Trial (RCT). *JAPA* **2016**, *24*, S32.
107. Panayiotou, G.; Paschalis, V.; Nikolaidis, M.G.; Theodorou, A.A.; Deli, C.K.; Fotopoulou, N.; Fatouros, I.G.; Koutedakis, Y.; Sampanis, M.; Jamurtas, A.Z. No adverse effects of statins on muscle function and health-related parameters in the elderly: An exercise study. *Scand. J. Med. Sci. Sport.* **2013**, *3*, 556–567. [[CrossRef](#)]
108. Theodorou, A.A.; Panayiotou, G.; Paschalis, V.; Nikolaidis, M.G.; Kyparos, A.; Mademli, L.; Grivas, G.V.; Vrabas, I.S. Stair descending exercise increases muscle strength in elderly males with chronic heart failure. *BMC Res. Notes* **2013**, *6*, 87. [[CrossRef](#)]
109. Takeshima, N.; Rogers, M.E.; Islam, M.M.; Yamauchi, T.; Watanabe, E.; Okada, A. Effect of concurrent aerobic and resistance circuit exercise training on fitness in older adults. *Eur. J. Appl. Physiol.* **2004**, *93*, 173–182. [[CrossRef](#)]
110. Lee, M.; Jun, W.; Sci, M.L.-K.J.S. Effects of a 12-week circuit exercise program on fall-related fitness in elderly women with sarcopenia. *Korean J. Sports Sci.* **2017**, *26*, 1123–1135.
111. Liberman, K.; Forti, L.N.; Beyer, I.; Bautmans, I. The effects of exercise on muscle strength, body composition, physical functioning and the inflammatory profile of older adults: A systematic review. *Curr. Opin. Clin. Nutr. Metab. Care* **2017**, *20*, 30–53. [[CrossRef](#)] [[PubMed](#)]
112. Bibas, L.; Levi, M.; Bendayan, M.; Mullie, L.; Forman, D.E.; Afilalo, J. Therapeutic interventions for frail elderly patients: Part I. Published randomized trials. *Prog. Cardiovasc. Dis.* **2014**, *57*, 134–143. [[CrossRef](#)] [[PubMed](#)]

113. Beaudart, C.; Reginster, J.-Y.Y.; Slomian, J.; Buckinx, F.; Quabron, A.; Dardenne, N.; Bruyère, O.; Locquet, M.; Bruyère, O. Prevalence of sarcopenia: The impact of different diagnostic cut-off limits. *J. Musculoskelet. Neuronal Interact.* **2014**, *14*, 425–431. [[CrossRef](#)]
114. Wei, N.; Pang, M.Y.; Ng, S.S.; Ng, G.Y. Optimal frequency/time combination of whole-body vibration training for improving muscle size and strength of people with age-related muscle loss (sarcopenia): A randomized controlled trial. *Geriatr. Gerontol. Int.* **2017**, *17*, 1412–1420. [[CrossRef](#)]
115. Chang, S.-F.; Lin, P.-C.; Yang, R.-S.; Yang, R.-J. The preliminary effect of whole-body vibration intervention on improving the skeletal muscle mass index, physical fitness, and quality of life among older people with sarcopenia. *BMC Geriatr.* **2018**, *18*, 17. [[CrossRef](#)]
116. Cardinale, M.; Pope, M.H. The effects of whole body vibration on humans: Dangerous or advantageous? *Acta Physiol. Hung.* **2003**, *90*, 195–206. [[CrossRef](#)]
117. Geirsdottir, O.G.; Arnarson, A.; Ramel, A.; Thorsdottir, I.; Briem, K.; Jonsson, P.V. Muscular strength and physical function in elderly adults 6–18 months after a 12-week resistance exercise program. *Scand. J. Public Health* **2015**, *43*, 76–82. [[CrossRef](#)]
118. Chen, H.T.; Chung, Y.C.; Chen, Y.J.; Ho, S.Y.; Wu, H.J. Effects of Different Types of Exercise on Body Composition, Muscle Strength, and IGF-1 in the Elderly with Sarcopenic Obesity. *J. Am. Geriatr. Soc.* **2017**, *65*, 827–832. [[CrossRef](#)]
119. Lau, R.W.; Liao, L.R.; Yu, F.; Teo, T.; Chung, R.C.; Pang, M.Y. The effects of whole body vibration therapy on bone mineral density and leg muscle strength in older adults: A systematic review and meta-analysis. *Clin. Rehabil.* **2011**, *25*, 975–988. [[CrossRef](#)]
120. Candow, D.G.; Chilibeck, P.D.; Forbes, S.C. Creatine supplementation and aging musculoskeletal health. *Endocrine* **2013**, *45*, 354–361. [[CrossRef](#)]
121. Katsanos, C.S.; Kobayashi, H.; Sheffield-Moore, M.; Aarsland, A.; Wolfe, R.R. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. *Am. J. Physiol. Metab.* **2006**, *291*, E381–E387. [[CrossRef](#)] [[PubMed](#)]
122. Dijk, F.J.; van Dijk, M.; Walrand, S.; van Loon, L.J.C.C.; van Norren, K.; Luiking, Y.C. Differential effects of leucine and leucine-enriched whey protein on skeletal muscle protein synthesis in aged mice. *Clin. Nutr. ESPEN* **2018**, *24*, 127–133. [[CrossRef](#)]
123. Wall, B.T.; Hamer, H.M.; de Lange, A.; Kiskini, A.; Groen, B.B.L.; Senden, J.M.G.; Gijsen, A.P.; Verdijk, L.B.; Van Loon, L.J.C. Leucine co-ingestion improves post-prandial muscle protein accretion in elderly men. *Clin. Nutr.* **2013**, *32*, 412–419. [[CrossRef](#)] [[PubMed](#)]
124. Deutz, N.E.P.; Pereira, S.L.; Hays, N.P.; Oliver, J.S.; Edens, N.K.; Evans, C.M.; Wolfe, R.R. Effect of β -hydroxy- β -methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. *Clin. Nutr.* **2013**, *32*, 704–712. [[CrossRef](#)]
125. Reidy, P.T.; Rasmussen, B.B. Role of Ingested Amino Acids and Protein in the Promotion of Resistance Exercise-Induced Muscle Protein Anabolism. *J. Nutr.* **2016**, *146*, 155–183. [[CrossRef](#)]
126. Bauer, J.; Biolo, G.; Cederholm, T.; Cesari, M.; Cruz-Jentoft, A.J.; Morley, J.E.; Phillips, S.; Sieber, C.; Stehle, P.; Teta, D.; et al. Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper from the PROT-AGE Study Group. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 542–559. [[CrossRef](#)]
127. Baum, J.; Wolfe, R. The Link between Dietary Protein Intake, Skeletal Muscle Function and Health in Older Adults. *Healthcare* **2015**, *3*, 529–543. [[CrossRef](#)]
128. Pennings, B.; Boirie, Y.; Senden, J.M.G.; Gijsen, A.P.; Kuipers, H.; Van Loon, L.J.C. Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men. *Am. J. Clin. Nutr.* **2011**, *93*, 997–1005. [[CrossRef](#)]
129. Kim, I.Y.; Shin, Y.A.; Schutzler, S.E.; Azhar, G.; Wolfe, R.R.; Ferrando, A.A. Quality of meal protein determines anabolic response in older adults. *Clin. Nutr.* **2018**, *37*, 2076–2083. [[CrossRef](#)]
130. Phillips, S.M.; Martinson, W. Nutrient-rich, high-quality, protein-containing dairy foods in combination with exercise in aging persons to mitigate sarcopenia. *Nutr. Rev.* **2019**, *77*, 216–229. [[CrossRef](#)]
131. Radavelli-Bagatini, S.; Zhu, K.; Lewis, J.R.; Prince, R.L. Dairy food intake, peripheral bone structure, and muscle mass in elderly ambulatory women. *J. Bone Miner. Res.* **2014**, *29*, 1691–1700. [[CrossRef](#)] [[PubMed](#)]
132. Radavelli-Bagatini, S.; Zhu, K.; Lewis, J.R.; Dhaliwal, S.S.; Prince, R.L. Association of Dairy Intake with Body Composition and Physical Function in Older Community-Dwelling Women. *J. Acad. Nutr. Diet.* **2013**, *113*, 1669–1674. [[CrossRef](#)]

133. Phillips, S.M. Dietary protein for athletes: From requirements to metabolic advantage. *Appl. Physiol. Nutr. Metab.* **2006**, *31*, 647–654. [[CrossRef](#)] [[PubMed](#)]
134. Phillips, S.M.; van Loon, L.J.C. Dietary protein for athletes: From requirements to optimum adaptation. *J. Sports Sci.* **2011**, *29*, S29–S38. [[CrossRef](#)]
135. Res, P.T.; Groen, B.; Pennings, B.; Beelen, M.; Wallis, G.A.; Gijzen, A.P.; Senden, J.M.G.; Van Loon, L.J.C. Protein ingestion before sleep improves postexercise overnight recovery. *Med. Sci. Sports Exerc.* **2012**, *44*, 1560–1569. [[CrossRef](#)] [[PubMed](#)]
136. Paddon-Jones, D.; Rasmussen, B.B. Dietary protein recommendations and the prevention of sarcopenia. *Curr. Opin. Clin. Nutr. Metab. Care* **2009**, *12*, 86–90. [[CrossRef](#)]
137. Mamerow, M.M.; Mettler, J.A.; English, K.L.; Casperson, S.L.; Arentson-Lantz, E.; Sheffield-Moore, M.; Layman, D.K.; Paddon-Jones, D. Dietary Protein Distribution Positively Influences 24-h Muscle Protein Synthesis in Healthy Adults. *J. Nutr.* **2014**, *144*, 876–880. [[CrossRef](#)]
138. Kerksick, C.M.; Arent, S.; Schoenfeld, B.J.; Stout, J.R.; Campbell, B.; Wilborn, C.D.; Taylor, L.; Kalman, D.; Smith-Ryan, A.E.; Kreider, R.B.; et al. International society of sports nutrition position stand: Nutrient timing. *J. Int. Soc. Sports Nutr.* **2017**, *14*, 1–21. [[CrossRef](#)]
139. Bosdou, J.; Konstantinidou, E.; Anagnostis, P.; Kolibianakis, E.; Goulis, D. Vitamin D and Obesity: Two Interacting Players in the Field of Infertility. *Nutrients* **2019**, *11*, 1455. [[CrossRef](#)]
140. Remelli, F.; Vitali, A.; Zurlo, A.; Volpato, S. Vitamin D Deficiency and Sarcopenia in Older Persons. *Nutrients* **2019**, *11*, 2861. [[CrossRef](#)]
141. Rondanelli, M.; Rigon, C.; Perna, S.; Gasparri, C.; Iannello, G.; Akber, R.; Alalwan, T.A.; Freije, A.M. Novel Insights on Intake of Fish and Prevention of Sarcopenia: All Reasons for an Adequate Consumption. *Nutrients* **2020**, *12*, 307. [[CrossRef](#)] [[PubMed](#)]
142. Hamilton, B. Vitamin D and Human Skeletal Muscle. *Scand. J. Med. Sci. Sports* **2009**, *20*, 182–190. [[CrossRef](#)] [[PubMed](#)]
143. Wilhelm-Leen, E.R.; Hall, Y.N.; DeBoer, I.H.; Chertow, G.M. Vitamin D deficiency and frailty in older Americans. *J. Intern. Med.* **2010**, *268*, 171–180. [[CrossRef](#)] [[PubMed](#)]
144. Sato, Y.; Iwamoto, J.; Kanoko, T.; Satoh, K. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: A randomized controlled trial. *Cerebrovasc. Dis.* **2005**, *20*, 187–192. [[CrossRef](#)] [[PubMed](#)]
145. Beudart, C.; Buckinx, F.; Rabenda, V.; Gillain, S.; Cavalier, E.; Slomian, J.; Petermans, J.; Reginster, J.Y.; Bruyère, O. The effects of vitamin d on skeletal muscle strength, muscle mass, and muscle power: A systematic review and meta-analysis of randomized controlled trials. *J. Clin. Endocrinol. Metab.* **2014**, *99*, 4336–4345. [[CrossRef](#)] [[PubMed](#)]
146. Annweiler, C.; Schott, A.M.; Berrut, G.; Fantino, B.; Beauchet, O. Vitamin D-related changes in physical performance: A systematic review. *J. Nutr. Health Aging* **2009**, *13*, 893–898. [[CrossRef](#)]
147. Cesari, M.; Penninx, B.W.J.H.; Pahor, M.; Lauretani, F.; Corsi, A.M.; Williams, G.R.; Guralnik, J.M.; Ferrucci, L. Inflammatory Markers and Physical Performance in Older Persons: The InCHIANTI Study. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2004**, *59*, M242–M248. [[CrossRef](#)]
148. Lauretani, F.; Semba, R.D.; Bandinelli, S.; Dayhoff-Brannigan, M.; Lauretani, F.; Corsi, A.M.; Guralnik, J.M.; Ferrucci, L. Carotenoids as Protection Against Disability in Older Persons. *Rejuvenation Res.* **2008**, *11*, 557–563. [[CrossRef](#)]
149. Smith, G.I.; Atherton, P.; Reeds, D.N.; Mohammed, B.S.; Rankin, D.; Rennie, M.J.; Mittendorfer, B. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: A randomized controlled trial. *Am. J. Clin. Nutr.* **2010**, *93*, 402–412. [[CrossRef](#)]
150. Mantzorou, M.; Pavlidou, E.; Vasios, G.; Tsagalioti, E.; Giaginis, C. Effects of curcumin consumption on human chronic diseases: A narrative review of the most recent clinical data. *Phyther. Res.* **2018**, *32*, 957–975. [[CrossRef](#)]
151. Heaton, L.E.; Davis, J.K.; Rawson, E.S.; Nuccio, R.P.; Witard, O.C.; Stein, K.W.; Baar, K.; Carter, J.M.; Baker, L.B. Selected In-Season Nutritional Strategies to Enhance Recovery for Team Sport Athletes: A Practical Overview. *Sport. Med.* **2017**, *47*, 2201–2218. [[CrossRef](#)] [[PubMed](#)]
152. Franceschi, F.; Feregalli, B.; Togni, S.; Cornelli, U.; Giacomelli, L.; Eggenhoffner, R.; Belcaro, G. A novel phospholipid delivery system of curcumin (Meriva®) preserves muscular mass in healthy aging subjects. *Eur. Rev. Med. Pharmacol. Sci.* **2016**, *20*, 762–766. [[PubMed](#)]

153. Alway, S.E.; McCrory, J.L.; Kearcher, K.; Vickers, A.; Frear, B.; Gilleland, D.L.; Bonner, D.E.; Thomas, J.M.; Donley, D.A.; Lively, M.W.; et al. Resveratrol Enhances Exercise-Induced Cellular and Functional Adaptations of Skeletal Muscle in Older Men and Women. *J. Gerontol. Ser. A* **2017**, *72*, 1595–1606. [[CrossRef](#)] [[PubMed](#)]
154. Robinson, S.; Denison, H.; Cooper, C.; Aihie Sayer, A. Prevention and optimal management of sarcopenia: A review of combined exercise and nutrition interventions to improve muscle outcomes in older people. *Clin. Interv. Aging* **2015**, *10*, 859. [[CrossRef](#)]
155. Abe, S.; Ezaki, O.; Suzuki, M. Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Increase Muscle Strength and Function in Frail Elderly Adults in a Randomized Controlled Trial. *J. Nutr.* **2016**, *146*, 1017–1026. [[CrossRef](#)]
156. Bauer, J.M.; Verlaan, S.; Bautmans, I.; Brandt, K.; Donini, L.M.; Maggio, M.; McMurdo, M.E.T.; Mets, T.; Seal, C.; Wijers, S.L.; et al. Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial. *J. Am. Med. Dir. Assoc.* **2015**, *16*, 740–747. [[CrossRef](#)]
157. Evans, M.; Guthrie, N.; Pezzullo, J.; Sanli, T.; Fielding, R.A.; Bellamine, A. Efficacy of a novel formulation of L-Carnitine, creatine, and leucine on lean body mass and functional muscle strength in healthy older adults: A randomized, double-blind placebo-controlled study. *Nutr. Metab.* **2017**, *14*, 7. [[CrossRef](#)]
158. Ispoglou, T.; White, H.; Preston, T.; McElhone, S.; McKenna, J.; Hind, K. Double-blind, placebo-controlled pilot trial of L-Leucine-enriched amino-acid mixtures on body composition and physical performance in men and women aged 65–75 years. *Eur. J. Clin. Nutr.* **2016**, *70*, 182–188. [[CrossRef](#)]
159. Leenders, M.; Verdijk, L.B.; van der Hoeven, L.; van Kranenburg, J.; Hartgens, F.; Wodzig, W.K.W.H.; Saris, W.H.M.; van Loon, L.J.C. Prolonged Leucine Supplementation Does Not Augment Muscle Mass or Affect Glycemic Control in Elderly Type 2 Diabetic Men. *J. Nutr.* **2011**, *141*, 1070–1076. [[CrossRef](#)]
160. Verlaan, S.; Maier, A.B.; Bauer, J.M.; Bautmans, I.; Brandt, K.; Donini, L.M.; Maggio, M.; McMurdo, M.E.T.; Mets, T.; Seal, C.; et al. Sufficient levels of 25-hydroxyvitamin D and protein intake required to increase muscle mass in sarcopenic older adults—The PROVIDE study. *Clin. Nutr.* **2018**, *37*, 551–557. [[CrossRef](#)]
161. Alemán-Mateo, H.; Carreón, V.R.; Macías, L.; Astiazaran-García, H.; Gallegos-Aguilar, A.C.; Enríquez, J.R.R. Nutrient-rich dairy proteins improve appendicular skeletal muscle mass and physical performance, and attenuate the loss of muscle strength in older men and women subjects: A single-blind randomized clinical trial. *Clin. Interv. Aging* **2014**, *9*, 1517. [[CrossRef](#)] [[PubMed](#)]
162. Dal Negro, R.W.; Testa, A.; Aquilani, R.; Tognella, S.; Pasini, E.; Barbieri, A.; Boschi, F. Essential amino acid supplementation in patients with severe COPD: A step towards home rehabilitation. *Monaldi Arch. Chest Dis.* **2012**, *77*, 67–75. [[CrossRef](#)] [[PubMed](#)]
163. Giannoulis, M.G.; Martin, F.C.; Nair, K.S.; Umpleby, A.M.; Sonksen, P. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? *Endocr. Rev.* **2012**, *33*, 314–377. [[CrossRef](#)] [[PubMed](#)]
164. Dodds, R.; Sayer, A.A. Sarcopenia. *Arq. Bras. Endocrinol. Metabol.* **2014**, *58*, 464–469. [[CrossRef](#)] [[PubMed](#)]
165. Xu, L.; Freeman, G.; Cowling, B.J.; Schooling, C.M. Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. *BMC Med.* **2013**, *11*, 108. [[CrossRef](#)] [[PubMed](#)]
166. Onder, G.; Penninx, B.W.J.H.; Balkrishnan, R.; Fried, L.P.; Chaves, P.H.M.; Williamson, J.; Carter, C.; Di Bari, M.; Guralnik, J.M.; Pahor, M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: An observational study. *Lancet* **2002**, *359*, 926–930. [[CrossRef](#)]
167. Sumukadas, D.; Witham, M.D.; Struthers, A.D.; McMurdo, M.E.T. Effect of perindopril on physical function in elderly people with functional impairment: A randomized controlled trial. *CMAJ* **2007**, *177*, 867–874. [[CrossRef](#)]
168. Burton, L.A.; Sumukadas, D.; Witham, M.D.; Struthers, A.D.; McMurdo, M.E.T. Effect of spironolactone on physical performance in older people with self-reported physical disability. *Am. J. Med.* **2013**, *126*, 590–597. [[CrossRef](#)]
169. Lynch, G.S. Emerging drugs for sarcopenia: Age-related muscle wasting. *Expert Opin. Emerg. Drugs* **2004**, *9*, 345–361. [[CrossRef](#)]

170. Stewart Coats, A.J.; Srinivasan, V.; Surendran, J.; Chiramana, H.; Vangipuram, S.R.K.G.; Bhatt, N.N.; Jain, M.; Shah, S.; Ali, I.A.B.H.; Fuang, H.G.; et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: Study design. *J. Cachexia. Sarcopenia Muscle* **2011**, *2*, 201–207.
171. Pötsch, M.S.; Tschirner, A.; Palus, S.; von Haehling, S.; Doehner, W.; Beadle, J.; Coats, A.J.S.; Anker, S.D.; Springer, J. The anabolic catabolic transforming agent (ACTA) espidolol increases muscle mass and decreases fat mass in old rats. *J. Cachexia. Sarcopenia Muscle* **2014**, *5*, 149–158. [[CrossRef](#)] [[PubMed](#)]
172. Rooks, D.; Roubenoff, R. Development of Pharmacotherapies for the Treatment of Sarcopenia. *J. Frailty Aging* **2019**, *8*, 120–130. [[PubMed](#)]
173. Hardee, J.P.; Lynch, G.S. Current pharmacotherapies for sarcopenia. *Expert Opin. Pharmacother.* **2019**, *20*, 1645–1657. [[CrossRef](#)] [[PubMed](#)]
174. Ohara, D.G.; Pegorari, M.S.; Oliveira dos Santos, N.L.; de Fátima Ribeiro Silva, C.; Monteiro, R.L.; Matos, A.P.; Jamami, M. Respiratory Muscle Strength as a Discriminator of Sarcopenia in Community-Dwelling Elderly: A Cross-Sectional Study. *J. Nutr. Health Aging* **2018**, *22*, 952–958. [[CrossRef](#)]



© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).